A malignant tumour arising from the endothelium of the peritoneum, and producing a mucoid ascitic fluid, The Journal of Pathology and Bacteriology, vol.xli, issue.2, pp.267-78, 1908. ,
DOI : 10.1002/path.1700120212
Asbestos cancers, J Natl Cancer Inst, vol.46, pp.5-9, 1971. ,
Epidemiology of peritoneal mesothelioma: a review, Annals of Oncology, vol.18, issue.6, pp.985-90, 2007. ,
DOI : 10.1093/annonc/mdl345
EARLY PERITONEAL MESOTHELIOMA: A TREATABLE MALIGNANCY, The Lancet, vol.326, issue.8462, pp.977-81, 1985. ,
DOI : 10.1016/S0140-6736(85)90526-4
Advances in Malignant Mesothelioma, New England Journal of Medicine, vol.353, issue.15, pp.1591-603, 2005. ,
DOI : 10.1056/NEJMra050152
Malignant peritoneal mesothelioma: a multicenter study on 81 cases, Annals of Oncology, vol.21, issue.2, pp.348-53, 2010. ,
DOI : 10.1093/annonc/mdp307
Multimodality therapy for malignant mesothelioma based on a study of natural history, The American Journal of Medicine, vol.68, issue.3, pp.356-62, 1980. ,
DOI : 10.1016/0002-9343(80)90103-5
Malignant peritoneal mesothelioma???Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent, Lung Cancer, vol.64, issue.2, pp.211-219, 2009. ,
DOI : 10.1016/j.lungcan.2008.08.013
Open-Label Study of Pemetrexed Alone or in Combination with Cisplatin for the Treatment of Patients with Peritoneal Mesothelioma: Outcomes of an Expanded Access Program, Clinical Lung Cancer, vol.7, issue.1, pp.40-46, 2005. ,
DOI : 10.3816/CLC.2005.n.020
Systemic chemotherapy in the management of malignant peritoneal mesothelioma, European Journal of Surgical Oncology (EJSO), vol.32, issue.6, pp.676-81, 2006. ,
DOI : 10.1016/j.ejso.2006.03.009
INTRACAVITARY DOXORUBICIN IN MALIGNANT EFFUSIONS, The Lancet, vol.313, issue.8112, p.390, 1979. ,
DOI : 10.1016/S0140-6736(79)92937-4
Long-term survival in patients with malignant peritoneal mesothelioma treated with irradiation, Cancer, vol.13, issue.3, pp.656-64, 1973. ,
DOI : 10.1002/1097-0142(197309)32:3<656::AID-CNCR2820320319>3.0.CO;2-U
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience, Journal of Clinical Oncology, vol.27, issue.36, pp.6237-6279, 2009. ,
DOI : 10.1200/JCO.2009.23.9640
Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC), European Journal of Cancer, vol.49, issue.15, pp.3140-3148, 2013. ,
DOI : 10.1016/j.ejca.2013.05.027
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group, Arch Pathol Lab Med, vol.133, pp.1317-1348, 2009. ,
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group, Archives of Pathology & Laboratory Medicine, vol.137, issue.5, pp.647-67, 2013. ,
DOI : 10.5858/arpa.2012-0214-OA
Multicystic and Well-differentiated Papillary Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC), Annals of Surgical Oncology, vol.417, issue.10, pp.2790-2797, 2007. ,
DOI : 10.1245/s10434-007-9475-8
A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*, Cancer, vol.17, issue.9, pp.1855-63, 2010. ,
DOI : 10.1002/cncr.25640
Diffuse malignant peritoneal mesothelioma ??? An update on treatment, Cancer Treatment Reviews, vol.38, issue.6, pp.605-617, 2012. ,
DOI : 10.1016/j.ctrv.2011.10.006
Pemetrexed Plus Gemcitabine As First-Line Chemotherapy for Patients With Peritoneal Mesothelioma: Final Report of a Phase II Trial, Journal of Clinical Oncology, vol.26, issue.21, pp.3567-72, 2008. ,
DOI : 10.1200/JCO.2007.15.2868
The Role of Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy, Annals of Surgical Oncology, vol.46, issue.4, pp.1093-100, 2013. ,
DOI : 10.1245/s10434-012-2845-x
R??seau RENAPE??: vers une nouvelle organisation des soins pour le traitement des tumeurs rares du p??ritoine. Description du r??seau et r??le des pathologistes, Annales de Pathologie, vol.34, issue.1, pp.4-8, 2014. ,
DOI : 10.1016/j.annpat.2014.01.008
Toxicity and response criteria of the Eastern Cooperative Oncology Group, AMERICAN JOURNAL OF CLINICAL ONCOLOGY, vol.5, issue.6, pp.649-55, 1982. ,
DOI : 10.1097/00000421-198212000-00014
Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis, Cancer Treat Res, vol.82, pp.359-74, 1996. ,
DOI : 10.1007/978-1-4613-1247-5_23
Peritonectomy procedures, Surgical Oncology Clinics of North America, vol.12, issue.3, pp.29-42, 1995. ,
DOI : 10.1016/S1055-3207(03)00048-6
Selection of patients and staging of peritoneal surface malignancies, World Journal of Gastrointestinal Oncology, vol.2, issue.1, pp.31-36, 2010. ,
DOI : 10.4251/wjgo.v2.i1.31
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis, Lung Cancer, vol.38, issue.2, pp.111-132, 2002. ,
DOI : 10.1016/S0169-5002(02)00180-0
Analysis of Factors Associated With Outcome in Patients With Malignant Peritoneal Mesothelioma Undergoing Surgical Debulking and Intraperitoneal Chemotherapy, Journal of Clinical Oncology, vol.21, issue.24, pp.4560-4567, 2003. ,
DOI : 10.1200/JCO.2003.04.150
Comprehensive management of diffuse malignant peritoneal mesothelioma, European Journal of Surgical Oncology (EJSO), vol.32, issue.6, pp.686-91, 2006. ,
DOI : 10.1016/j.ejso.2006.03.012
Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesotheliomay ,
Diffuse Malignant Peritoneal Mesothelioma: Failure Analysis Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC), Annals of Surgical Oncology, vol.14, issue.suppl, pp.463-72, 2008. ,
DOI : 10.1245/s10434-008-0219-1
Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: The Australian experience, Journal of Surgical Oncology, vol.27, issue.2, pp.109-122, 2009. ,
DOI : 10.1002/jso.21177
Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent or Progressive Diffuse Malignant Peritoneal Mesothelioma: Clinicopathologic Characteristics and Survival Outcome, Annals of Surgical Oncology, vol.107, issue.6, pp.1680-1685, 2014. ,
DOI : 10.1245/s10434-014-3977-y
Malignant Peritoneal Mesothelioma: Prognostic Factors and Oncologic Outcome Analysis, Annals of Surgical Oncology, vol.19, issue.4, pp.1159-65, 2014. ,
DOI : 10.1245/s10434-013-3358-y
Systemic therapies Manual of clinical oncology, pp.202-225, 1994. ,
Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20, Blood, vol.113, issue.16, pp.3765-72, 2009. ,
DOI : 10.1182/blood-2008-08-175125
Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs, PLoS ONE, vol.438, issue.1, p.63078, 2013. ,
DOI : 10.1371/journal.pone.0063078.t003
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma, Journal of Clinical Oncology, vol.21, issue.14, pp.2636-2680, 2003. ,
DOI : 10.1200/JCO.2003.11.136
Chemotherapy and targeted therapies for unresectable malignant mesothelioma, Lung Cancer, vol.73, issue.3, pp.256-63, 2011. ,
DOI : 10.1016/j.lungcan.2011.04.014
Safety and Activity of Anti???PD-L1 Antibody in Patients with Advanced Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2455-65, 2012. ,
DOI : 10.1056/NEJMoa1200694
Comparison of Evidence of Treatment Effects in Randomized and Nonrandomized Studies, JAMA, vol.286, issue.7, pp.821-851, 2001. ,
DOI : 10.1001/jama.286.7.821
Comparison of Treatment Effect Estimates From Prospective Nonrandomized Studies With Propensity Score Analysis and Randomized Controlled Trials of Surgical Procedures, Annals of Surgery, vol.259, issue.1, pp.18-25, 2014. ,
DOI : 10.1097/SLA.0000000000000256